파인메딕스
Financials
Valuation Metrics
파인메딕스's Market Cap is ₩304B. At end of 2025 it was ₩422B. Ranked #2003 of 2,410 in KR market (top 83%), #1265 of 1,631 on KOSDAQ (top 78%), #83 of 94 in Health Care Equipment & Services (top 88%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 30.44B KRW | KR#2,003/2,410 Sec#83/94 |
| Revenue | 11.43B KRW | KR#2,265/2,410 Sec#80/94 |
| Net Income | -599.4M KRW | KR—/2,410 Sec—/94 |
| Total Assets | 24.15B KRW | KR#2,356/2,410 Sec#91/94 |
| Net Assets | 19.13B KRW | KR#2,294/2,410 Sec#89/94 |
| Employees | 74 | KR#1,845/2,410 Sec#73/94 |
| Value | ||
| P/B | 1.59x | KR#1,879/2,410 Sec#63/94 |
| P/S | 2.66x | KR#1,983/2,410 Sec#65/94 |
| FCF Yield | -11.45% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | -3.13% | KR#1,722/2,410 Sec#59/94 |
| ROA | -2.48% | KR#1,790/2,410 Sec#61/94 |
| Op. Margin | -10.21% | KR#1,982/2,410 Sec#63/94 |
| Revenue Growth | -4.39% | KR#1,738/2,410 Sec#76/94 |
| Financial Health | ||
| Debt Ratio | 26.24% | KR#501/2,410 Sec#27/94 |
| Total Debt | 1.93B KRW | KR#1,908/2,410 Sec#71/94 |
| FCF | -3.49B KRW | KR#1,416/2,410 Sec#49/94 |
| Cash | 4.07B KRW | KR#2,077/2,410 Sec#80/94 |
| Current Ratio | 10.83x | KR#87/2,410 Sec#11/94 |
| Performance | ||
| 1Y Return | -30.73% | KR#1,391/2,410 Sec#44/94 |
| 1M Return | -13.44% | KR#1,460/2,410 Sec#58/94 |
| From 52W High | -41.39% | KR#707/2,410 Sec#25/94 |
| 1Y MDD | -54.65% | KR#1,165/2,410 Sec#45/94 |
| Trading | ||
| Volume | 3,731 shares | KR#2,044/2,410 Sec#86/94 |
| Trading Value | 20.3M KRW | KR#1,904/2,410 Sec#77/94 |
| Foreign Own. | 1.17% | KR#1,950/2,410 Sec#70/94 |
| Per Share | ||
| EPS | -107 KRW | KR—/2,410 Sec—/94 |
| BPS | 3,400 KRW | KR#1,782/2,410 Sec#50/94 |
Company Info
Fine Medic, established in 2009, is a specialized manufacturer of advanced digestive endoscopic procedure instruments, listed on KOSDAQ in 2024. The company has localized endoscopic incision knives, snares, and injectors, securing over 20% domestic market share and expanding sales in Japan, Europe, and the U.S. based on CE and FDA certifications. Leveraging the CEO's more than 20 years of clinical experience, Fine Medic has established a unified development system to promptly productize the needs of the medical field. It is headquartered in Dong-gu, Daegu Metropolitan City.